When viewing this topic in a different language, you may notice some differences in the way the content is structured, but it still reflects the latest evidence-based guidance.

Last reviewed: 21 Mar 2025
Last updated: 21 Aug 2024

Summary

Definition

History and exam

Key diagnostic factors

  • presence of risk factors
  • unknown toxin ingestion or exposure
  • confusion, disorientation, agitation
  • nausea, vomiting, epigastric pain
  • fever, sweating, warm extremities, bounding pulses
  • dyspnoea
  • tachypnoea, hyperventilation, Kussmaul's respirations
  • tinnitus and/or deafness
  • malaise and/or dizziness
  • movement disorders, asterixis, stupor
  • confusion and/or delirium (irritability, hallucinations, deterioration in activities of daily living)
  • coma and/or papilloedema
  • convulsions
  • rales plus low oxygen saturation (signs of heart failure)

Other diagnostic factors

  • volume depletion/dehydration
  • skin rash
  • ventricular arrhythmias and asystole
  • haematemesis
  • disseminated intravascular coagulation

Risk factors

  • ingestion of ≥125 mg/kg salicylate
  • ingestion of oil of wintergreen (methyl salicylate)
  • ingestion of bismuth subsalicylate
  • history of self-harm or suicide attempt
  • children aged ≤3 years and adults aged ≥70 years

Diagnostic investigations

1st investigations to order

  • plasma salicylate concentration
  • ABG
  • serum electrolyte panel, urea and creatinine
  • serum prothrombin time (PT), activated PTT, INR
  • FBC
  • capillary blood glucose
  • ECG

Treatment algorithm

Contributors

Expert advisers

Marianne Gillings, BPharm(Hons), MBBS, MRCP(UK), PGDip(MedTox), FRCEM

Emergency Medicine Consultant

Gloucestershire Hospitals

UK

Disclosures

MG is a member of the RCEM Toxicology steering group (voluntary post). MG is co-author of the RCEM Best practice guideline Suspected Cannabinoid Hyperemesis Syndrome in the Emergency Department (November 2022). MG is co-author of the RCEM guidelines Suspected Nitrous Oxide Toxicity in Emergency Departments (April 2023). MG is a member of the Trial Steering Committee for the HiSNAP trial (voluntary).

Acknowledgements

BMJ Best Practice would like to gratefully acknowledge the previous team of expert contributors, whose work is retained in parts of the content:

Johann Grundlingh, MBChB, FCEM, FFICM, EDICM, DFMS, DipMedTox, MMedTox, MSB, ERT, MEWI, MBA

Emergency Medicine Consultant

Royal London Hospital

Barts Health NHS Trust

Honorary Senior Lecturer

Queen Mary University

London

UK

JG declares that he has no competing interests.

James Kelly, MA (Oxon), MPhil, MA, MBBS, PGDME

Education Academy Fellow in Critical Care

Newham University Hospital

London

UK

JK declares that he has no competing interests.

Chris Hoyte, MD

Medical Toxicology Fellowship Program Director

Rocky Mountain Poison and Drug Safety

Denver

Associate Professor

Department of Emergency Medicine

University of Colorado School of Medicine

Aurora

CO

CH declares that he has no competing interests.

Eric Lavonas, MD, MS

Attending Physician

Department of Emergency Medicine and Rocky Mountain Poison and Drug Safety

Denver Health

Denver

Professor

Department of Emergency Medicine

University of Colorado School of Medicine

Aurora

CO

Peer reviewers

Andreas Crede, MBChB, FCEM, MMed Emergency Medicine, PgDip Toxicology

Consultant

Emergency Department

Sheffield Teaching Hospitals NHS Foundation Trust

Sheffield

UK

Disclosures

AC declares that he has no competing interests.

Use of this content is subject to our disclaimer